Novo, Nordisk

Novo Nordisk Foundation granted DKK 10 billion to benefit people and the planet in milestone year

07.08.2025 - 18:04:00

Novo Nordisk Foundation Denmark United States of America United Kingdom

held north of Copenhagen, which gathered 150 international experts to discuss the interplay of major health and sustainability challenges.A global partnership with the Gates Foundation and Wellcome to address a series of global health challenges.The launch of Denmark's first AI supercomputer, Gefion, powered by NVIDIA technology, to accelerate research in academia and industry in areas including healthcare, quantum computing, and the green transition.The launch of the Partnership for Education of Health Professionals (PEP) in Kenya, in partnership with the Ministry of Health in Kenya and six African-based institutions. This initiative aims to strengthen the education of health professionals in cardiometabolic diseases.A new office in Nairobi, Kenya, as part of the Novo Nordisk Foundation's internationalisation efforts and increased engagement in East Africa.Regenerative medicine, with a focus on advancing and applying stem-cell based therapies, was made an explicit part of the Novo Nordisk Foundation's strategy.More than DKK 2.8 billion (€375 million) awarded through grants in open competition. This included:Funding for six projects across three themes through the Challenge Programme, with two projects seeking to advance nuclear energy research.Funding for 41 exceptional researchers across various scientific disciplines in grants through the 2024 Research Leader ProgrammeA grant of DKK 500 million (€67 million) for the Ancient Environmental Genomics Initiative for Sustainability (AEGIS) project, which aims to enhance crop resilience and agroecosystem sustainability. This project was also funded by Wellcome.Launch of a partnership with CARB-X to support the early-stage development of tools to prevent, diagnose and treat the most dangerous drug-resistant bacterial infections.A contribution of DKK 1 billion (£134 million) to the BRIGHT initiative at the Technical University of Denmark, which aims to accelerate the development of biosolutions and strengthen the bio-based economy.The Foundation's first major grant in the mental health space, an award of DKK 150 million (€20.1 million) for "Best for Us", a project aiming to help children and adolescents affected by mental distress or mental illness. This project was also funded by the Obel Family Foundation.A DKK 202 million (€27.1 million) grant for Campus Kalundborg, aiming to create a unique educational environment for students within the biomanufacturing and biosolutions sphere.

In addition, the Foundation committed up to DKK 10 billion (€1.35 billion) to convert land in Denmark to enable space for more nature and biodiversity and for agricultural production based on modern technologies. These funds are to be awarded for projects over a period of ten years, with the first grant being awarded in December 2024 for a rewilding project along the Kongeåen River.

Watch more: CEO Mads Krogsgaard Thomsen and members of the Foundation leadership discuss the why behind the Foundation's major initiatives in 2024.

About the Novo Nordisk Foundation
Established in Denmark in 1924, the Novo Nordisk Foundation is an enterprise foundation with philanthropic objectives. The vision of the Foundation is to improve people's health and the sustainability of society and the planet. The Foundation's mission is to progress research and innovation in the prevention and treatment of cardiometabolic and infectious diseases as well as to advance knowledge and solutions to support a green transformation of society.
www.novonordiskfonden.dk/en

Cision View original content:https://www.prnewswire.co.uk/news-releases/novo-nordisk-foundation-granted-dkk-10-billion-1-35-billion-to-benefit-people-and-the-planet-in-milestone-year-302363712.html

@ prnewswire.co.uk

Weitere Meldungen

AKTIEN IM FOKUS: Novo Nordisk erholt - FDA will gegen Wegovy-Kopie vorgehen Die Aktien von Novo Nordisk DK0062498333 haben am Freitag mit einem Kursplus von gut 5 Prozent auf 295,60 dänische Kronen einen Stabilisierungsversuch gestartet. (Boerse, 06.02.2026 - 11:49) weiterlesen...

ANALYSE-FLASH: JPMorgan belässt Novo Nordisk auf 'Overweight' - Ziel 350 Kronen Die US-Bank JPMorgan hat Novo Nordisk DK0062498333 auf "Overweight" mit einem Kursziel von 350 dänischen Kronen belassen. (Boerse, 05.02.2026 - 22:35) weiterlesen...

AKTIEN IM FOKUS: Novo Nordisk und Eli Lilly fallen - Bericht: neue Konkurrenz Die Aktien von Novo Nordisk DK0062498333 und Eli Lilly US5324571083 sind am Donnerstagnachmittag unter Druck geraten. (Boerse, 05.02.2026 - 15:20) weiterlesen...

Pharmahersteller Lilly glänzt mit Prognose - Aktie zieht vorbörslich kräftig an Anders als Konkurrent Novo Nordisk DK0062498333 rechnet der US-Pharmahersteller Lilly US5324571083 auch in diesem Jahr mit einem kräftigen Umsatzanstieg. (Boerse, 04.02.2026 - 13:17) weiterlesen...

Aktien Europa: Anleger halten sich zurück - Novo Nordisk brechen ein Europas Börsen haben am Mittwoch auf der Stelle getreten. (Boerse, 04.02.2026 - 11:58) weiterlesen...

AKTIE IM FOKUS: Novo Nordisk brechen ein - Hargreaves: 'schlanker Ausblick' Die Aussicht auf sinkende Umsätze des Pharmaherstellers Novo Nordisk DK0062498333 in diesem Jahr hat den Kurs der Aktie am Mittwoch einbrechen lassen. (Boerse, 04.02.2026 - 10:22) weiterlesen...